Ambrose Healthcare Ltd. is delighted to announce that it has won the Best Startup Biotech Company Award at the prestigious OBN Awards 2024, held on 20 November in London.
The OBN Awards acknowledge the most impactful life science companies, entrepreneurs, and innovations across the UK. The Best Startup Biotech Company category specifically recognizes the early-stage company making the most significant strides in transforming healthcare through scientific and business advancements.
“We are incredibly honored to win this OBN award,” said Georgia Wilson Waterworth, Co-founder and COO of Ambrose Healthcare. “At Ambrose Healthcare, we are seeking to drive change in the rare disease treatment landscape through rapidly progressing clinical development of in-licensed drug candidates and other solutions. The recognition from OBN Ltd reinforces Ambrose Healthcare's growing reputation as a leader in the rare disease space.”
Ambrose Healthcare’s most advanced drug candidate, within its late-stage portfolio, is a novel molecule being developed for gastrointestinal symptoms of cystic fibrosis. This is a growing quality of life challenge for these patients who are now living longer, for which there is no approved treatment.
Ambrose Healthcare is raising the last £500,000 of an EIS approved seed round to prepare for executing a potentially pivotal clinical study which, if successful, can be the basis for filing for regulatory approval utilizing rare disease regulations.
The award comes at an exciting time for Ambrose Healthcare, and follows last year’s success in winning National Life Sciences Startup of the Year 2023.
About Ambrose Healthcare
UK based Ambrose Healthcare is an entrepreneurial pharmaceutical company working to drive change and provide solutions in rare diseases. It is building a late clinical stage rare disease drug portfolio through licensing and acquisitions, to complete development and commercialise. It is utilizing rare disease regulatory pathways designed to provide an accelerated route to market, with reduced development costs, timelines, and market protections.
About Ambrose Healthcare’s most advanced drug program
Ambrose Healthcare’s most advanced drug candidate renzapride is a novel treatment being developed and prepared for a potentially pivotal study for gastrointestinal (GI) symptoms of cystic fibrosis (CF).
Renzapride is an investigational prokinetic agent with a dual mode of action, being both a 5HTP4 agonist and a 5HTP3 antagonist, which can act throughout the gastrointestinal tract. It has demonstrated an attractive efficacy and safety profile in clinical studies involving >3,000 patients.
Results include three Phase 2 clinical studies in Constipation Predominant Irritable Bowel Syndrome (IBS-c) which reported statistically significant (p<0.05) improvements in bowel motility, and reduction in pain, bloating and feelings of nausea. These symptoms are also experienced by many CF patients.
These improvements have been reconfirmed in a Phase 3 trial, where they were studied as secondary endpoints in IBS-c.
An independent report on the potential of renzapride to treat GI symptoms experienced by CF patients is available upon request.
About OBN Ltd
OBN Ltd is the UK’s leading life sciences membership organization, supporting companies from start-ups to mature enterprises through networking, partnering, and advocacy. Its annual OBN Awards celebrate the outstanding achievements of businesses and individuals making significant contributions to the life sciences industry.
Forward looking statement
While Ambrose Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Ambrose Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Ambrose Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.